Deliberations on Management Nomination and Compensation by the Nomination and Compensation Committee
First written in FY2019. 1 of 2 entries say "Reframed", first in FY2021. Latest entry: FY2021.
Fuji Pharma moved to the "Worse" side of this theme in 2021, 3 years before the typical company in this theme (2024).
The whole theme swung hardest in 2025: 9 of 89 companies on the "Worse" side.
5 other companies' latest entry also says "Reframed".
- FY2021ReframedAnnual report
「As an advisory body to the Board of Directors, we have established a Nomination and Compensation Committee comprising 3 members: 2 outside directors, Hirai Keiji (平井 敬二), who serves as chair, and Miyake Minesaburo (三宅 峰三郎), and Representative Director and President Iwai Takayuki (岩井 孝之).」
The composition of the Nomination and Compensation Committee is described as 2 outside directors and the Representative Director and President, rather than the previous composition of 2 outside directors and a director. - FY2019First statedAnnual report
「As an advisory body to the Board of Directors, we have established a Nomination and Compensation Committee comprising 3 members: 2 outside directors, Hirai Keiji (平井 敬二), who serves as chair, and Miyake Minesaburo (三宅 峰三郎), and director Kamide Toyoyuki (上出 豊幸). The committee works to strengthen corporate governance and ensure transparency and fairness when considering the appointment and compensation of senior executives.」
The Company has established a 3-member Nomination and Compensation Committee, including 2 outside directors, as an advisory body to the Board of Directors, and disclosed the mechanism for ensuring transparency and fairness in executive appointments and compensation.